Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12967-021-02798-2 http://scihub22266oqcxt.onion/10.1186/s12967-021-02798-2 33789686!8010485!33789686     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Transl+Med 2021 ; 19 (1): 132 Nephropedia Template TP {{tp|p=33789686|t=2021. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis |pdf=|usr=}}{{33789686}} gab.com Text Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis JO: J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33789686 #FOAvip Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects' safety is mandatory especially in oncology, in consideration of cancer patients' particular frailty. We examined the proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and/or IgG positive subjects in three different groups from Istituto Nazionale Tumori - IRCCS "Fondazione G. Pascale" in Naples (Campania region, Italy): cancer patients treated with Innovative Immunotherapy (Immune Checkpoint Inhibitors, ICIs), cancer patients undergoing standard Chemotherapies (CHTs) and healthcare providers. 9 out of 287 (3.1%) ICIs patients resulted positive, with a significant lower percentage in respect to CHTs patients (39 positive subjects out of 598, 6.5%) (p = 0.04). There was no statistically significant difference between ICIs cohort and healthcare providers, 48 out of 1050 resulting positive (4.6%). Performing a Propensity Score Matching based on gender and tumor stage, the effect of treatment on seropositivity was analyzed through a regression logistic model and the ICIs treatment resulted to be the only protective factor significantly (p = 0.03) associated with positivity (odds ratio-OR: 0.41; 95% confidence interval-CI 0.18-0.91). According to these preliminary data, ICIs would appear to be a protective factor against the onset of COVID-19 infection. Twit Text FOAVip Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis ????J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33789686 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33789686 #FOAvip English Wikipedia <ref>{{Cite pmid|33789686}}</ref> Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis #MMPMID33789686 Isgro MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA J Transl Med 2021[Mar]; 19 (1): 132 PMID33789686show ga Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects' safety is mandatory especially in oncology, in consideration of cancer patients' particular frailty. We examined the proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and/or IgG positive subjects in three different groups from Istituto Nazionale Tumori - IRCCS "Fondazione G. Pascale" in Naples (Campania region, Italy): cancer patients treated with Innovative Immunotherapy (Immune Checkpoint Inhibitors, ICIs), cancer patients undergoing standard Chemotherapies (CHTs) and healthcare providers. 9 out of 287 (3.1%) ICIs patients resulted positive, with a significant lower percentage in respect to CHTs patients (39 positive subjects out of 598, 6.5%) (p = 0.04). There was no statistically significant difference between ICIs cohort and healthcare providers, 48 out of 1050 resulting positive (4.6%). Performing a Propensity Score Matching based on gender and tumor stage, the effect of treatment on seropositivity was analyzed through a regression logistic model and the ICIs treatment resulted to be the only protective factor significantly (p = 0.03) associated with positivity (odds ratio-OR: 0.41; 95% confidence interval-CI 0.18-0.91). According to these preliminary data, ICIs would appear to be a protective factor against the onset of COVID-19 infection. |*Immunotherapy[MESH] |*SARS-CoV-2/immunology[MESH] |Aged[MESH] |Antibodies, Viral/blood[MESH] |Antineoplastic Agents/therapeutic use[MESH] |COVID-19/epidemiology/immunology/*prevention & control[MESH] |Female[MESH] |Humans[MESH] |Immune Checkpoint Inhibitors/*therapeutic use[MESH] |Immunoglobulin G/blood[MESH] |Immunoglobulin M/blood[MESH] |Italy/epidemiology[MESH] |Logistic Models[MESH] |Male[MESH] |Middle Aged[MESH] |Neoplasms/complications/immunology/*therapy[MESH] |Pandemics[MESH] |Retrospective Studies[MESH]Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a(epmc).pdf DeepDyve Pubget Overpricing